AI-powered clinical decision support and lab-as-a-service for hospitals drive healthtech to its strongest quarter on AletheiaAI in March 2026
Indian healthtech startups averaged FCI 59 in March 2026 on AletheiaAI. AI-powered clinical decision support, diagnostic lab-as-a-service for hospitals, and digital therapeutics with regulatory approval led the cohort. Direct-to-consumer health brands remained weak.
India Healthtech Sector: March 2026 Snapshot
March 2026 was healthtech's strongest month in Q1, with 22 decks reviewed and an average FCI of 59. CDSCO's updated SaMD (Software as a Medical Device) regulatory pathway accelerated investor confidence in clinical AI.
What Investors Are Rewarding
AI-powered clinical decision support — radiology AI reading chest X-rays, pathology AI for cancer detection, and triage algorithms for emergency medicine — averaged FCI 68. Qure.ai's FDA clearance created a reference point for Indian clinical AI fundability.
Lab-as-a-service for hospitals — centralised processing for small hospital labs, quality management systems for diagnostic chains, and NABL-accreditation-as-a-service — averaged FCI 65. Metropolis and SRL Diagnostics' franchise models proved the economics.
Digital therapeutics with CDSCO approval — clinically validated apps for diabetes management, hypertension control, and pulmonary rehabilitation — averaged FCI 63. CDSCO's SaMD guidelines published in late 2025 created a regulatory pathway.
Where Decks Are Failing
Aggregator apps for doctor discovery averaged FCI 43. The segment is perceived as a feature of Practo, not a standalone business.
Pharmacy tech without PAN India licensing averaged FCI 44. State-by-state drug licensing complexity makes this high regulatory risk.
Notable Trends
- Preventive oncology — Risk stratification and early detection platforms for cancer averaging FCI 66, citing India's 1.4M annual new cancer cases.
- Ayurveda and integrative medicine SaaS — Digitising Ayush practitioners and creating outcome data averaged FCI 58.
- Hospital revenue cycle management — Claim automation for insurance TPA settlements averaged FCI 63.
Investor Sentiment
INVEST/PASS: 35%/65%. CDSCO regulatory pathway clarity was March's primary conviction driver for clinical-grade AI.